Last reviewed · How we verify
Albuterol-sulphate
Albuterol sulfate is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation.
Albuterol sulfate is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation. Used for Acute bronchospasm and reversible obstructive airway disease, Asthma (acute and maintenance therapy), Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Albuterol-sulphate |
|---|---|
| Also known as | (Proventil ®) |
| Sponsor | NYU Langone Health |
| Drug class | Beta-2 adrenergic agonist (short-acting) |
| Target | Beta-2 adrenergic receptor (ADRB2) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Albuterol activates beta-2 adrenergic receptors on bronchial smooth muscle, triggering a cascade that increases intracellular cAMP and leads to smooth muscle relaxation. This results in rapid airway dilation and improved airflow, providing symptomatic relief of bronchoconstriction. It is commonly used as a rescue medication for acute bronchospasm and as a maintenance therapy in obstructive airway diseases.
Approved indications
- Acute bronchospasm and reversible obstructive airway disease
- Asthma (acute and maintenance therapy)
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Nervousness or anxiety
- Headache
- Palpitations
- Muscle cramps
- Tachycardia
Key clinical trials
- A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (PHASE3)
- A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma (PHASE3)
- A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma (PHASE4)
- A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma (PHASE3)
- Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (PHASE3)
- Clinical Assessment of Acupuncture for the Treatment of Chronic Asthma (NA)
- PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (PHASE3)
- Magnesium Trial in Acute Asthma in Emergency Department (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albuterol-sulphate CI brief — competitive landscape report
- Albuterol-sulphate updates RSS · CI watch RSS
- NYU Langone Health portfolio CI